BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30372646)

  • 1. Clinicopathological analysis of borderline ovarian tumours and risk factors related to recurrence: experience of single institution.
    Sozen H; Vatansever D; Topuz S; Iyibozkurt C; Kandemir H; Yalçin I; Onder S; Yavuz E; Salihoglu Y
    J Obstet Gynaecol; 2019 Feb; 39(2):253-258. PubMed ID: 30372646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (≤40 years old) with borderline ovarian tumors.
    Fang C; Zhao L; Chen X; Yu A; Xia L; Zhang P
    BMC Cancer; 2018 Nov; 18(1):1147. PubMed ID: 30463533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.
    du Bois A; Ewald-Riegler N; de Gregorio N; Reuss A; Mahner S; Fotopoulou C; Kommoss F; Schmalfeldt B; Hilpert F; Fehm T; Burges A; Meier W; Hillemanns P; Hanker L; Hasenburg A; Strauss HG; Hellriegel M; Wimberger P; Keyver-Paik MD; Baumann K; Canzler U; Wollschlaeger K; Forner D; Pfisterer J; Schröder W; Münstedt K; Richter B; Kommoss S; Hauptmann S;
    Eur J Cancer; 2013 May; 49(8):1905-14. PubMed ID: 23490647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of fertility-sparing surgery and further prognostic factors in borderline tumors of the ovary.
    Westermann T; Karabeg E; Heitz F; Traut A; Plett H; Moubarak M; Welz J; Heikaus S; Lax S; du Bois A; Harter P
    Int J Gynecol Cancer; 2024 Jun; 34(6):898-905. PubMed ID: 38627034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk.
    Vasconcelos I; de Sousa Mendes M
    Eur J Cancer; 2015 Mar; 51(5):620-31. PubMed ID: 25661104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Borderline ovarian tumors: a retrospective cohort study on single institution experience, practice patterns and outcomes.
    Abdallah R; Chamsy D; Dagher C; Hajjar R; El Housheimi A; Seoud M; Khalil A
    J Obstet Gynaecol; 2022 Nov; 42(8):3600-3604. PubMed ID: 36250321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for recurrence of borderline ovarian tumours: A tertiary centre experience.
    Demirkiran F; Sal V; Bese T; Tokgozoglu N; Erenel H; Sofiyeva N; Kahramanoglu I; Arvas M
    J Obstet Gynaecol; 2016 Nov; 36(8):1036-1040. PubMed ID: 27559007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Predictors of Recurrence and Prognostic Value of Lymph Node Involvement in the Serous Borderline Ovarian Tumor.
    Qian XQ; Hua XP; Wu JH; Shen YM; Cheng XD; Wan XY
    Int J Gynecol Cancer; 2018 Feb; 28(2):279-284. PubMed ID: 29194193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Epidemiology and Risk Factors of Relapse, Follow-up and Interest of a Completion Surgery].
    Margueritte F; Sallee C; Lacorre A; Gauroy E; Larouzee E; Chereau E; De La Motte Rouge T; Koskas M; Gauthier T
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):248-259. PubMed ID: 32004784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fertility-sparing surgery for young patients with borderline ovarian tumors (BOTs): single institution experience.
    Chen RF; Li J; Zhu TT; Yu HL; Lu X
    J Ovarian Res; 2016 Mar; 9():16. PubMed ID: 26988551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates.
    Vasconcelos I; Darb-Esfahani S; Sehouli J
    BJOG; 2016 Mar; 123(4):498-508. PubMed ID: 26705090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of factors that impact recurrence in patients with borderline ovarian tumors.
    Chen X; Fang C; Zhu T; Zhang P; Yu A; Wang S
    J Ovarian Res; 2017 Apr; 10(1):23. PubMed ID: 28376898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of borderline ovarian tumours.
    Gershenson DM
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():49-59. PubMed ID: 27780698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors.
    Vancraeynest E; Moerman P; Leunen K; Amant F; Neven P; Vergote I
    Int J Gynecol Cancer; 2016 Oct; 26(8):1399-406. PubMed ID: 27465897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence and prognostic factors in borderline ovarian tumors.
    Ayhan A; Guvendag Guven ES; Guven S; Kucukali T
    Gynecol Oncol; 2005 Sep; 98(3):439-45. PubMed ID: 16009407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fertility preserving surgical treatment of borderline ovarian tumour: long-term consequence for fertility and recurrence.
    Marcickiewicz J; Brännström M
    Acta Obstet Gynecol Scand; 2006; 85(12):1496-500. PubMed ID: 17260228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for borderline ovarian tumors.
    Franchi D; Boveri S; Radice D; Portuesi R; Zanagnolo V; Colombo N; Testa AC
    Am J Obstet Gynecol; 2016 Dec; 215(6):756.e1-756.e9. PubMed ID: 27443811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What women want: Fertility sparing surgery in Borderline ovarian tumours patients and pregnancy outcome.
    Candotti G; Peiretti M; Mangili G; Bergamini A; Candiani M; Cioffi R; Mais V; Rabaiotti E; Bocciolone L
    Eur J Surg Oncol; 2020 May; 46(5):888-892. PubMed ID: 31722834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.
    Trillsch F; Mahner S; Woelber L; Vettorazzi E; Reuss A; Ewald-Riegler N; de Gregorio N; Fotopoulou C; Schmalfeldt B; Burges A; Hilpert F; Fehm T; Meier W; Hillemanns P; Hanker L; Hasenburg A; Strauss HG; Hellriegel M; Wimberger P; Baumann K; Keyver-Paik MD; Canzler U; Wollschlaeger K; Forner D; Pfisterer J; Schroeder W; Muenstedt K; Richter B; Kommoss F; Hauptmann S; du Bois A
    Ann Oncol; 2014 Jul; 25(7):1320-1327. PubMed ID: 24618151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.